1127-13-5

Basic information

• Product Name: 4-hydroxy-Bicyclo[2.2.2]octane-1-carboxylic acid
• Synonyms: 4-hydroxy-Bicyclo[2.2.2]octane-1-carboxylic acid
• CAS NO: 1127-13-5
• Molecular Formula: C₉H₁₄O₃
• Molecular Weight: 170.20566
• Mol File: 1127-13-5.mol

Chemical Properties

• Melting Point: 224-226 °C(bomb tube)
• Boiling Point: 322.2±42.0 °C(Predicted)
• Appearance: /
• Density: 1.398±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.84±0.10(Predicted)
• CAS DataBase Reference: 4-hydroxy-Bicyclo[2.2.2]octane-1-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-hydroxy-Bicyclo[2.2.2]octane-1-carboxylic acid(1127-13-5)
• EPA Substance Registry System: 4-hydroxy-Bicyclo[2.2.2]octane-1-carboxylic acid(1127-13-5)

Safety Data

• Hazardous Substances Data: 1127-13-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Hydroxy-Bicyclo[2.2.2]octane-1-carboxylic acid is used as a reagent/reactant for the preparation and structure-activity relations of tricyclic imidazoline derivatives. These derivatives have been identified as potent and selective adenosine A1 receptor antagonists, which play a crucial role in various physiological processes and have potential therapeutic applications in treating conditions such as neurodegenerative diseases, cardiovascular disorders, and certain types of cancer.

Upstream product

• 1659-95-6 dimethyl 1,3-cyclohexadiene-1,4-dicarboxylate 
• 1659-67-2 dimethyl bicyclo[2.2.2]oct-2-ene-1,4-dicarboxylate 
• 100-21-0 terephthalic acid 
• 72653-14-6 1,5-di-tert-butyl 3-ethyl 3-acetylpentane-1,3,5-tricarboxylate 
• 72948-75-5 tris-ethyl 3-acetylpentane-1,3,5-tricarboxylate 
• 72948-76-6 ethyl 4-hydroxy-2-oxobicyclo[2.2.2]octane-1-carboxylate 
• 72653-21-5 ethyl 1-acetyl-4-oxocyclohexane-1-carboxylate 
• 1403864-72-1 ((4-(methoxycarbonyl)bicyclo[2.2.2]octane-1-carbonyl)oxy)silver 
• 94-60-0 dimethyl 1,4-cyclohexane dicarboxylate 
• 72948-77-7 ethyl 4-hydroxyspiro[bicyclo[2.2.2]octane-2,2'-[1,3]dithiolane]-1-carboxylate 
• 1659-96-7 1,4-dibromo-trans-cyclohexane-1,4-dicarboxylic acid dimethyl ester 
• 18720-35-9 bicyclo[2.2.2]octane-1,4-dicarboxylic acid monomethyl ester 
• 1459-96-7 dimethyl bicyclo[2.2.2]octane-1,4-dicarboxylate 
• 23062-51-3 methyl 4-bromo-bicyclo[2.2.2]octane-1-carboxylate 

Downstream Products

• 23062-53-5 methyl 4-hydroxybicyclo<2.2.2>octane-1-carboxylate 
• 1252672-84-6 tert-butyl (4-hydroxybicyclo[2.2.2]octan-1-yl)carbamate 
• 94994-28-2 4-methoxybicyclo<2.2.2>octane-1-carboxaldehyde 
• 1403864-73-2 benzyl 4-hydroxybicyclo[2.2.2]octan-1-ylcarbamate 
• 66789-33-1 4-p-Nitrobenzolsulfonyloxy-bicyclo<2.2.2>octan-1-carbonsaeuremethylester 
• 773-34-2 4-methoxybicyclo<2.2.2>octane-1-carboxylic acid 

Relevant articles and documents

A Molecular Torsion Balance Study: A Nearby Anionic Group Exerts Little Influence on Hydrophobic Interactions between Nonpolar Surfaces

Polar groups have a solvent ordering effect on water and therefore may affect hydrophobic binding energies for nearby lipophilic surfaces. This would mean that determinations of excess surface free energy association energies require consideration of nearby polar functional groups. This paper reports results of a study to measure this possible effect. It was concluded from the models used here that an anionic polar group nearby a hydrophobic surface has little or no effect on the magnitude of hydrophobic association.

ISOXAZOLYL-CARBONYLOXY AZABICYCLO[3.2.1]OCTANYL COMPOUNDS AS FXR ACTIVATORS

The disclosure relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): wherein L1, L2, A, B, R1, R2, R3, and R4 are described herein.

COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are Diaminopyrimidine Compounds having the following structures: wherein R1, R2, R3, and R4 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidine Compound, and methods for treating or preventing liver fibrotic disorders or a condition treatable or preventable by inhibition of a JNK pathway.

NOVEL AMIDE AND AMIDINE DERIVATIVES AND USES THEREOF

The present invention relates to inhibitors of 11-β-hydroxysteroid dehydrogenase type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.

HETEROBICYCLIC METALLOPROTEASE INHIBITORS

The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP- 13 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP- 13 inhibitors.